AstraZeneca’s COVID-19 vaccine begins phase 3

AstraZeneca, the biopharmaceutical company, said its COVID-19 vaccine AZD1222 expands into a phase 3 clinical trial in the U.S

Trader 2

AstraZeneca, the biopharmaceutical company, said its COVID-19 vaccine AZD1222 expands into a phase 3 clinical trial in the U.S., enrolling up to 30,000 adults. Meanwhile, the company reported that its Imfinzi has been approved in the European Union for the treatment of extensive-stage small cell lung cancer. Also, it said its Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase 3 DAPA-CKD trial.


From a chartist’s point of view, the stock price has entered into a consolidation move and is capped by the key resistance threshold at 8811p. The 50-DMA started to flatten out indicating a lack of momentum in the short term. The Daily Relative Strength Index (RSI, 14) is capped by a declining trend line. Readers may want to consider opening Short positions below the key resistance level at 8811 with 8048p and 7685p as targets (congestion zone). Alternatively, a push above 8811p would open a path to see 9400p. 

Source: GAIN Capital, TradingView

More from Equities

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.